Surgical treatment in oligometastatic breast cancer

Metastatic breast cancer (MBC) management is based on systemic treatment (ST), while the local therapy role remains controversial. We present the case of a 36-year-old woman with a diagnosis of hormone receptor-positive and human epidermal growth factor receptor type 2-positive breast cancer and iso...

Descripción completa

Detalles Bibliográficos
Autores principales: Vargas, Catalina, Maiz, Cristóbal, Navarro, María Elena, Oddó, David, Sánchez, César, Bustos, Marisa, Camus, Mauricio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592707/
https://www.ncbi.nlm.nih.gov/pubmed/31281428
http://dx.doi.org/10.3332/ecancer.2019.931
Descripción
Sumario:Metastatic breast cancer (MBC) management is based on systemic treatment (ST), while the local therapy role remains controversial. We present the case of a 36-year-old woman with a diagnosis of hormone receptor-positive and human epidermal growth factor receptor type 2-positive breast cancer and isolated sternal metastasis, who received neoadjuvant ST with complete remission and later primary tumour surgery. Oligometastatic patients are a subgroup of MBC that can benefit from aggressive local therapies, even with curative intent.

Ejemplares similares